𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Entry and competition in generic biologics

✍ Scribed by Henry G. Grabowski; David B. Ridley; Kevin A. Schulman

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
189 KB
Volume
28
Category
Article
ISSN
0143-6570

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Patents for several blockbuster biological products are expected to expire soon. The Food and Drug Administration is examining whether biologics can and should be treated like pharmaceuticals with regard to generics. In contrast with pharmaceuticals, which are manufactured through chemical synthesis, biologics are manufactured through fermentation, a process that is more variable and costly. Regulators might require extensive clinical testing of generic biologics to demonstrate equivalence to the branded product. The focus of the debate on generic biologics has been on legal and health concerns, but there are important economic implications. We combine a theoretical model of generic biologics with regression estimates from generic pharmaceuticals to estimate market entry and prices in the generic biologic market. We find that generic biologics will have high fixed costs from clinical testing and from manufacturing, so there will be less entry than would be expected for generic pharmaceuticals. With fewer generic competitors, generic biologics will be relatively close in price to branded biologics. Policy makers should be prudent in estimating financial benefits of generic biologics for consumers and payers. We also examine possible government strategies to promote generic competition. Copyright Β© 2007 John Wiley & Sons, Ltd.

πŸ“œ SIMILAR VOLUMES

Generic competition and market exclusivi
Generic competition and market exclusivity periods in pharmaceuticals
✍ Henry G. Grabowski; Margaret Kyle πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 170 KB

## Abstract In this paper we examine generic competition and market exclusivity periods for pharmaceuticals experiencing their initial generic entry between 1995 and 2005. We find that generic competition has increased over several dimensions. First, an increasing number of drugs are subject to gen

Entry of foreign banks in Shanghai: impl
Entry of foreign banks in Shanghai: implications for business strategies in an increasingly competitive market
✍ M.K. Leung; T. Young πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 144 KB

## Abstract This paper uses a simple mean‐variance choice model as the basis of a duration analysis of the factors determining the decision of a foreign bank to establish a branch in Shanghai, the fast developing financial centre in China. Bank attributes, namely region of origin, parent bank size,

Stopping immunomodulators and biologics
Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission
✍ Kofi Clarke; Miguel Regueiro πŸ“‚ Article πŸ“… 2012 πŸ› John Wiley and Sons 🌐 English βš– 86 KB

The emergence of biologic response modifiers and earlier use of immunomodulators for inflammatory bowel disease (IBD) patients have improved outcomes. Durable remissions have been achieved in many IBD patients on these treatments, but the duration of treatment and identifying which patients may stop

DOMESTIC MARKETS AND INTERNATIONAL COMPE
DOMESTIC MARKETS AND INTERNATIONAL COMPETITIVENESS: GENERIC AND PRODUCT-SPECIFIC COMPETENCIES IN THE ENGINEERING SECTOR
✍ ASHISH ARORA; ALFONSO GAMBARDELLA πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 820 KB

This paper develops a theory of how the size of the domestic market shapes firm competencies. Our theory implies that large markets are beneficial even if factors such as economies of scale or learning effects are absent. We validate our model by an international comparison of the performance of fir